Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients

Transplantation

Volumn 83, Issue 3, 2007, Pages 282-289

  Ekberg, Henrik ^a   Kyllönen, Lauri ^b   Madsen, Søren ^c   Grave, Gisle ^d   Solbu, Dag ^e   Holdaas, Hallvard ^f  

^a LUND UNIVERSITY   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Smerud Medical Research International AS   (Norway)

^e Medical Department   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adverse events; Gastrointestinal; Health related quality of life; Immunosuppression; Kidney transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ADULT; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FEMALE; FINLAND; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEALTH SURVEY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIGESTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NORWAY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; SHORT FORM 36; SWEDEN; TREATMENT OUTCOME;

ADULT; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 33846980744     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000251923.14697.f5     Document Type: Review

References (59)

1. Annual Report of the US Scientific Registry for Transplant Recipients. 2004 annual report of the U.S. scientific registry for transplant recipients and the organ procurement and transplantation network: transplant data 2002-2004. Washington, DC: U.S. Department of Health and Human Services, 2004.
2. Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajardo D, Valderrabano F. Changes in quality of life after renal transplantation. Am J Kidney Dis 1998; 32(1): 93.
3. Franke GH, Reimer J, Philipp T, Heemann U. Aspects of quality of life through end-stage renal disease. Qual Life Res 2003; 12(2): 103.
4. Hathaway DK, Winsett RP, Johnson C, et al. Post kidney transplant quality of life prediction models. Clin Transplant 1998; 12(3): 168.
5. Johnson CD, Wicks MN, Milstead J, et al. Racial and gender differences in quality of life following kidney transplantation. Image J Nurs Sch 1998; 30(2): 125.
6. Matas AJ, Halbert RJ, Barr ML, et al. Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. Clin Transplant 2002; 16(2): 113.
7. Matas AJ, McHugh L, Payne WD, et al. Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation. Clin Transplant 1998; 12(3): 233.
8. Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005; 18(6): 643.
9. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Nephrol Dial Transplant 2002; 17(Suppl 4): 1.
10. Hilbrands LB, Hoitsma AJ, Koene RA. The effect of immunosuppressive drugs on quality of life after renal transplantation. Transplantation 1995; 59(9): 1263.
11. Lutkes P, Franke G, Witzke O, et al. [Quality of life following transplantation. The impact of a new immunosuppressive substance.] Zentralbl Chir 1999; 124(2): 90.
12. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63(7): 977.
13. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002; 13(1): 277.
14. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65(11): 1450.
15. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol 1998; 160 (6 Pt 1): 1982.
16. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004; 17(10): 609.
17. Sarkio S, Halme L, Kyllonen L, Salmela K. Severe gastrointestinal complications after 1,515 adult kidney transplantations. Transpl Int 2004; 17(9): 505.
18. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19(6): 779.
19. Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005; 23(5): 461.
20. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006; 101(1): 18.
21. Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002; 97(8): 1986.
22. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998; 26(4): 250.
23. Hagman E. SF-36-terveyskysely koetun terveyden ja toimintakyvyn mittarina. Suomen Lääkärileht 1996; 51: 3534.
24. Bjorner JB, Damsgaard MT, Watt T, et al. Danish Manual for the SF-36. Copenhagen: Lif, 1997.
25. Sullivan M, Karlsson J. SF-36: Swedish manual and interpretation guide. Gothenburg: Gothenburg University, 1994.
26. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston: New England Medical Centre, 1993.
27. Sullivan M, Karlsson J, Ware JE Jr. The Swedish SF-36 Health Survey I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 1995; 41(10): 1349.
28. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28(8): 681.
29. Kleinman L, Faull R, Walker R, et al. Gastrointestinal-specific patientreported outcome instruments differentiate between renal transplant patients with or without GI complications. Transplant Proc 2005; 37(2): 846.
30. Strid H, Simren M, Johansson AC, et al. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transplant 2002; 17(8): 1434.
31. Dimenas E, Carlsson G, Glise H, et al. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8.
32. Scallan E, Majowicz SE, Hall G, et al. Prevalence of diarrhoea in the community in Australia, Canada, Ireland, and the United States. Int J Epidemiol 2005; 34(2): 454.
33. Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998; 42(5): 690.
34. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 48.
35. Agreus L, Talley NJ, Svardsudd K, et al. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. Scand J Gastroenterol 2000; 35(2): 142.
36. Agreus L, Svardsudd K, Nyren O, Tibblin G. The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol 1994; 29(2): 102.
37. Walter S, Hallbook O, Gotthard R, et al. A population-based study on bowel habits in a Swedish community: prevalence of faecal incontinence and constipation. Scand J Gastroenterol 2002; 37(8): 911.
38. Wildner-Christensen M, Møller Hansen J, Schaffalitzky De Muckadell OB. Risk factors for dyspepsia in a general population: Non-steriodal anti-inflammatory drugs, cigarette smoking and unemployment are more important than Helicobacter pylori infection. Scand J Gastroenterol 2006; 41(2): 149.
39. Tsuji-Hayashi Y, Fukuhara S, Green J, et al. Health-related quality of life among renal-transplant recipients in Japan. Transplantation 1999; 68(9): 1331.
40. Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population - the Kalixanda study. Aliment Pharmacol Ther 2006; 23(12): 1725.
41. Liker H, Hungin AP, Wiklund I. Management of reflux disease in primary care: the patient perspective. J Am Board Fam Pract 2005; 18(5): 393.
42. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord 2003; 3 Suppl 2: S3.
43. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17(3): 141.
44. Fisher A, Schwartz M, Mor E, et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. Transplant Proc 1994; 26(6): 3106.
45. Emre S, Genyk Y, Schluger LK, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int 2000; 13(1): 73.
46. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64(3): 436.
47. Maes BD, Evenepoel P, Kuypers D, et al. Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clin Transplant 2003; 17(3): 171.
48. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345(8961): 1321.
49. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61(7): 1029.
50. Buchler M, Lebranchu Y, Beneton M, et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 2005; 78(1): 34.
51. El Haggan W, Ficheux M, Debruyne D, et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. Transplant Proc 2005; 37(2): 864.
52. Meier-Kriesche HU, Davies NM, Grinyo J, et al. Mycophenolate so-dium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. Am J Transplant 2005; 5(5): 1164.
53. McColl E, Junghard O, Wiklund I, Revicki D. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005; 100(1): 11.
54. Fallone CA, Guyatt GH, Armstrong D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004; 20(10): 1161.
55. Kizilisik AT, Feurer ID, VanBuren DH, et al. Effects of diabetes and cadaveric organs on functional performance and health-related quality of life after kidney transplantation. Am J Surg 2003; 186(5): 535.
56. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14(9): 2381.
57. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17(3): 200.
58. Morrissey PE, Reinert S, Yango A, et al. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. Transplant Proc 2005; 37(5): 2044.
59. Jones RH, Hungin AP, Phillips J, Mills JG. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995; 1: 149.